tradingkey.logo
tradingkey.logo
Buscar

Myriad Genetics Inc

MYGN
Añadir a la lista de seguimiento
4.295USD
+0.045+1.06%
Horarios del mercado ETCotizaciones retrasadas 15 min
405.45MCap. mercado
PérdidaP/E TTM

Más Datos de Myriad Genetics Inc Compañía

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.

Información de Myriad Genetics Inc

Símbolo de cotizaciónMYGN
Nombre de la empresaMyriad Genetics Inc
Fecha de salida a bolsaOct 06, 1995
Director ejecutivoRaha (Samraat S)
Número de empleados2700
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 06
Dirección322 North 2200 West
CiudadSALT LAKE CITY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal84116
Teléfono18015843600
Sitio Webhttps://myriad.com/
Símbolo de cotizaciónMYGN
Fecha de salida a bolsaOct 06, 1995
Director ejecutivoRaha (Samraat S)

Ejecutivos de Myriad Genetics Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
296.53K
-58.32%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
267.80K
+58.57%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
191.84K
+31.12%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
171.89K
+26.01%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
93.72K
-36.29%
Dr. Dale Muzzey
Dr. Dale Muzzey
Chief Scientific Officer
Chief Scientific Officer
86.18K
-135.01%
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
59.05K
+8.47%
Mr. Benjamin Richard (Ben) Wheeler
Mr. Benjamin Richard (Ben) Wheeler
Chief Financial Officer
Chief Financial Officer
21.32K
-1299.87%
Ms. S. Louise Phanstiel, CPA
Ms. S. Louise Phanstiel, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Heiner Dreismann, Ph.D.
Dr. Heiner Dreismann, Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
296.53K
-58.32%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
267.80K
+58.57%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
191.84K
+31.12%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
171.89K
+26.01%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
93.72K
-36.29%
Dr. Dale Muzzey
Dr. Dale Muzzey
Chief Scientific Officer
Chief Scientific Officer
86.18K
-135.01%

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Myriad Genetics Inc?

Los cinco principales accionistas de Myriad Genetics Inc son: Mr. Mark S. Verratti

¿Cuántas instituciones poseen acciones de Myriad Genetics Inc (MYGN)?

A fecha de 2026Q1, 539 instituciones poseen acciones de Myriad Genetics Inc, con un valor de mercado combinado de aproximadamente 102.95M, lo que representa el 109.00% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -7290509.00.

¿Cuál es la mayor fuente de ganancias de Myriad Genetics Inc?

El 2026Q1, el segmento empresarial Hereditary Cancer generó la ganancia más alta para Myriad Genetics Inc, ascendiendo a 372.40M y representando el 45.17% de la ganancia total.
KeyAI